Special Issue "Recent Advances in T Cell Biology"
Deadline for manuscript submissions: closed (31 January 2023) | Viewed by 2361
Interests: pathology; hemathology; immunology; immunoncology; oncology; gynecological oncology
Special Issues, Collections and Topics in MDPI journals
Special Issue in Journal of Personalized Medicine: Precision Medicine in Gynaecological Oncology
Special Issue in Journal of Clinical Medicine: Advances in Diagnosis and Treatment of Gynecological Malignancies: Part II
Special Issue in Microorganisms: Advances in SARS-CoV-2 Infection
Special Issue in Pathogens: Oncopathogens
Special Issue in Viruses: Viral Infections in Gynecological Diseases
Special Issue in International Journal of Molecular Sciences: Pathogenesis and Immunology of Cytomegalovirus
Immunoncology is the innovative sub-branch of oncology based on the use of modern immunotherapies in the fight against cancer; in practice, it consists in the stimulation of the immune system to treat cancer, by exploiting the innate immune surveillance and by boosting the body’s antitumor defenses. Immunotherapies can be categorized as active or passive: active immunotherapy directly targets neoplastic cells via the immune system, for example by adoptive T cells transfer or Chimeric Antigen Receptor (CAR) T cells or monoclonal antibodies, while passive immunotherapy indirectly enhances the natural ability of the immune system to attack cancer (e.g., checkpoint inhibitors and cytokines). The main concept behind CAR-T immunotherapy is the engineering of T lymphocytes, in order to more effectively recognize, target and destroy cancer cells. To date the best results have been obtained in the treatment of B-cell acute lymphoblastic leukemia by tisagenlecleucel, diffuse large B-cell lymphoma and follicular lymphoma by axicabtagene ciloleucel and lisocabtagene maraleucel, mantle cell lymphoma by brexucabtagene autoleucel, and multiple myeloma by ciltacabtagene autoleucel and idecabtagene vicleucel; however, solid malignancies have shown low response rates due to the difficulty of CAR-T cells to be efficiently trafficked into the neoplastic core, and for the presence of hostile tumor microenvironments. Moreover, identification of key antigens has been challenging, since they must be highly expressed on the majority of cancer cells, but almost absent in normal tissues. Aim of this Special Issue is to illustrate all recent advances in T cells biology, including Tumor Infiltrating Lymphocytes (TILs), with particular emphasis on those advancements that increase the efficacy and delivery of CAR-T cells in solid malignancies, avoiding at the same time their possible side effects, such as neurotoxicity and cytokine release syndrome. The Special Issue is mainly addressed to pathologists, hematologists, oncologists, immunologists, surgeons, biologists, biotechnologists, bioengineers, pharmacologists, and chemists.
Dr. Luca Roncati
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- solid cancer
- liquid cancer
- cancer immunotherapy
- Tumor-Infiltrating Lymphocytes (TILs)
- T cells
- T cells biology
- Chimeric Antigen Receptor (CAR) T cells
- CAR-T therapy
- adoptive T cells transfer